Granules India Ltd vs Lasa Supergenerics Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Granules India Ltd is ₹ 699.95 as of 04 May 09:28 . The P/E Ratio of Granules India Ltd changed from 13.7 on March 2021 to 23.5 on March 2025 . This represents a CAGR of 11.40% over 5 yearsThe P/E Ratio of Lasa Supergenerics Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Granules India Ltd changed from ₹ 7511 crore on March 2021 to ₹ 11814 crore on March 2025 . This represents a CAGR of 9.48% over 5 yearsThe Market Cap of Lasa Supergenerics Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Granules India Ltd for the Mar '26 is ₹ 1495 crore as compare to the Dec '25 revenue of ₹ 1384 crore. This represent the growth of 8.02% The revenue of Lasa Supergenerics Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Granules India Ltd for the Mar '26 is ₹ 376.79 crore as compare to the Dec '25 ebitda of ₹ 304.46 crore. This represent the growth of 23.76% The ebitda of Lasa Supergenerics Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Granules India Ltd changed from ₹ 134.65 crore to ₹ 201.57 crore over 8 quarters. This represents a CAGR of 22.35% The net profit of Lasa Supergenerics Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The Dividend Payout of Granules India Ltd changed from 6.72 % on March 2021 to 11.39 % on March 2025 . This represents a CAGR of 11.13% over 5 yearsThe Dividend Payout of Lasa Supergenerics Ltd changed from 4.46 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 years .

About Granules India Ltd

Granules India Limited is a large-scale vertically integrated company founded in March, 1991 manufacturing Active Pharmaceutical Ingredient (API), Pharmaceutical Formulation Intermediate (PFI) and Finished Dosage (FD).
With a strong presence across all three vertical, the company has created a leadership position in the off-patent drugs segment along with ensuring a strong presence in first line of defense' products such as Paracetamol, Ibuprofen, Metformin and Guaifenesin.
Granules India is the preferred supplier for some of the world's leading pharma branded and generics companies. Granules Life Sciences Private Limited, based in Hyderabad, Telangana, is a wholly owned subsidiary of Granules India.
It significantly enhances the Company's finished dosage manufacturing capabilities, contributing an additional 10 billion dosage units annually.

About Lasa Supergenerics Ltd

Lasa Supergenerics Limited was incorporated on March 11, 2016.
The Company is primarily engaged in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc. The Company is a vertically integrated group spanning the entire veterinary, animal and human healthcare value chain-from discovery-to-delivery, with established credentials in research, manufacturing and global marketing.
The Company is a veterinary API manufacturing entity, which was acquired in April, 2012.
The manufacturing facility is located at Mahad & Chiplun, in the Konkan region of Maharashtra.
It specialises in catalyst chemistry' and manufactures anthelmintic / veterinary API products with largest production capabilities and product categories in India.

FAQs for the comparison of Granules India Ltd and Lasa Supergenerics Ltd

Which company has a larger market capitalization, Granules India Ltd or Lasa Supergenerics Ltd?

Market cap of Granules India Ltd is 17,327 Cr while Market cap of Lasa Supergenerics Ltd is 39 Cr

What are the key factors driving the stock performance of Granules India Ltd and Lasa Supergenerics Ltd?

The stock performance of Granules India Ltd and Lasa Supergenerics Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Granules India Ltd and Lasa Supergenerics Ltd?

As of May 4, 2026, the Granules India Ltd stock price is INR ₹699.25. On the other hand, Lasa Supergenerics Ltd stock price is INR ₹7.96.

How do dividend payouts of Granules India Ltd and Lasa Supergenerics Ltd compare?

To compare the dividend payouts of Granules India Ltd and Lasa Supergenerics Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.